Top Tweets for #datodxd
@DFCI_BreastOnc & @TheTBCRC are leading the TRADE-DXd trial, a phase 2 trial evaluating the efficacy of sequential #AntibodyDrugConjugates (trastuzumab deruxtecan (#TDXd) followed by datopotamab deruxtecan (#DatoDXd), or vice versa, for patients with advanced HER2 negative #BreastCancer.
For more information call 877-338-7425 or visit: https://t.co/7A4GxwAMo8
PI: Ana Garrido-Castro #ADCs
@DFCI_BreastOnc & @TheTBCRC are leading the TRADE-DXd trial, a phase 2 trial evaluating the efficacy of sequential #AntibodyDrugConjugates (trastuzumab deruxtecan (#TDXd) followed by datopotamab deruxtecan (#DatoDXd), or vice versa, for patients with advanced HER2 negative #BreastCancer.
For more information call 877-338-7425 or visit: https://t.co/7A4GxwAeyA
PI: Ana Garrido-Castro #ADCs
#datoDXd FDA approved 1st line TNBC among pts who are not a candidate for immunotherapy
Not 1️⃣, not 2️⃣, but now 3️⃣ approvals in #bcsm this month!
#vepdegestrant
#TDxd neoadj/adj
#datodxD 1st L
https://t.co/FXeEAWVkqE
@DFCI_BreastOnc & @TheTBCRC are leading the TRADE-DXd trial, a phase 2 trial evaluating the efficacy of sequential #AntibodyDrugConjugates (trastuzumab deruxtecan (#TDXd) followed by datopotamab deruxtecan (#DatoDXd), or vice versa, for patients with advanced HER2 negative #BreastCancer.
For more information call 877-338-7425 or visit: https://t.co/7A4GxwAeyA
PI: Ana Garrido-Castro #ADCs
@DFCI_BreastOnc & @TheTBCRC are leading the #TRADE-DXd trial, a phase 2 trial evaluating the efficacy of sequential #AntibodyDrugConjugates (trastuzumab deruxtecan (#TDXd) followed by datopotamab deruxtecan (#DatoDXd), or vice versa, for patients with advanced HER2 negative #BreastCancer.
For more information call 877-338-7425 or visit: https://t.co/7A4GxwAeyA
PI: Ana Garrido-Castro #ADCs
Osimertinib plus Dato-DXd (4 or 6 mg/kg) was investigated in EGFR-mutated advanced NSCLC post-PD on first-line osimertinib. For osimertinib plus Dato-DXd 6 mg/kg, median PFS was 11.7 months; DoR and OS were encouraging. ORCHARD
#osimertinib #datodxd
https://t.co/odZaFyiNM0
@DFCI_BreastOnc & @TheTBCRC are leading the TRADE-DXd trial, a phase 2 trial evaluating the efficacy of sequential #AntibodyDrugConjugates (trastuzumab deruxtecan (#TDXd) followed by datopotamab deruxtecan (#DatoDXd), or vice versa, for patients with advanced HER2 negative #BreastCancer.
For more information call 877-338-7425 or visit: https://t.co/7A4GxwAeyA
PI: Ana Garrido-Castro #ADCs
First-line metastatic TNBC has officially changed!
The key question is no longer “chemo or not?”
It’s which ADC, for which patient, with which toxicity trade-off.
Welcome to the ADC-first era in metastatic TNBC.
#ASCO #ESMO #TNBC #BreastCancer #ADC #Sacituzumab #DatoDXd #Oncology
2025 approvals: Summary of 5 new drugs/indications in #BreastCancer & #GynOnc by Santa aka @US_FDA
1. #DatoDXd
2. #TDXd x2
3. #Imlunestrant
4. #Avutometinib/#Defactinib: Ovarian Ca
#bcsm #OncTwitter #MedTwitter #HappyHolidays #MerryChristmas
2024 approvals: Summary of 8 new drugs/indications in #BreastCancer & #GynOnc by @US_FDA
1. #Ribociclib
2. #Inavolisib
3. #Pembrolizumab x2
4. #Mirvetuximab
5. #Tisotumab
6. #Dostarlimab
7. #Durvalumab
#bcsm #gyncsm #OncTwitter #MedTwitter #HappyHolidays
2025 approvals: Summary of 9 new drugs/indications in #LungCancer by @US_FDA
1. #TelisoV
2. #Taletrectinib
3. #DatoDXd
4. #Sunvozertinib
5. #Zongertinib
6. #Lurbinectedin (w/Atezo)
7. #Sevabertinib
8. #Tarlatamab
9. SubQ #Amivantamab
#lcsm #OncTwitter #MedTwitter
2024 approvals: Summary of 14 new drugs/indications in #LungCancer by @US_FDA
1. #Tepotinib
2. #Osimertinib x2
3. #Alectinib
4. #Tarlatamab
5. #Zenocutuzumab
6. #Durvalumab x2
7. #Amivantamab x2
8. #Nivolumab
9. #Ensartinib
#lcsm #OncTwitter #MedTwitter
More data to change first-line therapy in patients with advanced triple-negative #PDL1- (or IO ineligible) #BreastCancer after #ESMO25: another great presentation by superstar @RebeccaDSing of the #TropionBreast02 trial (NO crossover allowed)
@myESMO @OncoAlert #datoDXd #bcsm
@DFCI_BreastOnc & @TheTBCRC are leading the TRADE-DXd trial, a phase 2 trial evaluating the efficacy of sequential #AntibodyDrugConjugates (trastuzumab deruxtecan (#TDXd) followed by datopotamab deruxtecan (#DatoDXd), or vice versa, for patients with advanced HER2 negative #BreastCancer.
For more information call 877-338-7425 or visit: https://t.co/7A4GxwAMo8
PI: #AnaGarridoCastro #ADCs
@DFCI_BreastOnc & @TheTBCRC are leading the TRADE-DXd trial, a phase 2 trial evaluating the efficacy of sequential #AntibodyDrugConjugates (trastuzumab deruxtecan (#TDXd) followed by datopotamab deruxtecan (#DatoDXd), or vice versa, for patients with advanced HER2 negative #BreastCancer.
For more information call 877-338-7425 or visit: https://t.co/7A4GxwAMo8
PI: Ana Garrido-Castro #ADCs
🫁 Pooled analysis from TROPION-Lung05 & Lung01.
Datopotamab deruxtecan showed ORR 43%, DoR 7 mo, PFS 5.8 mo, OS 15.6 mo in heavily pretreated EGFR-mut NSCLC. Acceptable safety, no new signals.
📖 @JTOonline
DOI 👉🏻 https://t.co/n6CmfOGZVw
#CánCare #NSCLC #EGFR #DatoDXd #lungcancer
VJ Oncology - Paolo Tarantino on Investigating Dato-DXd in HER2- Breast Cancer Brain Metastases
@VJOncology @PTarantinoMD @DanaFarber
https://t.co/XsB13iWbNw
#OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #DatoDXd #BreastCancer #mBC #DATOBase @CancerWorldmag
🚨 New! US expert Delphi consensus on the prevention and management of #stomatitis in patients treated with #DatopotamabDeruxtecan
🔓https://t.co/rG6o7vByPS
@hoperugo @dradityabardia @ErikaHamilton9 @jhaveri_komal @BCJoyceO @sands_jacob @stolaney1 #OralMucositis #DatoDXd
@DFCI_BreastOnc & @TheTBCRC are leading the TRADE-DXd trial, a phase 2 trial evaluating the efficacy of sequential #AntibodyDrugConjugates (trastuzumab deruxtecan (#TDXd) followed by datopotamab deruxtecan (#DatoDXd), or vice versa, for patients with advanced HER2 negative #BreastCancer.
For more information call 877-338-7425 or visit: https://t.co/7A4GxwAeyA
TROPION-PanTumor01 trial for advanced #BladderCancer. @UroDocAsh interviews Dr. Funda Meric-Bernstam @MDAndersonNews on the #TROPIONPanTumor01 trial results in #urothelialcancer. #DatoDXd shows a 25% ORR in heavily pretreated patients, with 76% maintaining disease control at 6 months! Promising durability & manageable safety. 🔬💊 Watch now > https://t.co/KgvFco8meW
#HawaiiLung25 @JSabari @nyulangone discusses #DatoDxd (Trop2 ADC) latest approval for EGFR+ NSCLC post osi progression ➡️based on Ph2 TropionLung 01,05 trials w ORR 45%
➡️ He asks the experts is Dato-Dxd a 2nd line option?
@DAVAOnc @EGFRResisters
Last Seen Hashtags on Sotwe
nolimit(**)** +filter:native_video
Seen from United States
قحاب_شراميط_جده
momson() nolimit()* filter:native_video
Seen from Australia
สวิงพิจิตร
Seen from Thailand
omegle
Seen from Argentina
monkeyapp
Seen from United States
tekirdağesc
Seen from Turkey
92i beurette
Seen from France
ankaratraveſtileri
Seen from Turkey
istanbul gay
Seen from Turkey
Most Popular Users
Elon Musk 
@elonmusk
240.9M followers
Barack Obama
@barackobama
119.2M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Cristiano Ronaldo
@cristiano
111.5M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
97.9M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.1M followers
KATY PERRY
@katyperry
88.2M followers
Taylor Swift
@taylorswift13
82M followers
Lady Gaga
@ladygaga
73.5M followers
Virat Kohli
@imvkohli
70.7M followers
Kim Kardashian
@kimkardashian
70M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64.2M followers
Neymar Jr
@neymarjr
63.5M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.9M followers
Selena Gomez
@selenagomez
61.2M followers
X
@x
60.8M followers